Aurinia Pharmaceuticals Inc. logo AUPH - Aurinia Pharmaceuticals Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 11
HOLD 3
SELL 0
STRONG
SELL 0
| PRICE TARGET: $16.00 DETAILS
HIGH: $16.00
LOW: $16.00
MEDIAN: $16.00
CONSENSUS: $16.00
UPSIDE: 5.12%

Stock News

Aurinia Pharmaceuticals (NASDAQ:AUPH) vs. Cronos Group (NASDAQ:CRON) Financial Comparison

Aurinia Pharmaceuticals (NASDAQ:AUPH) vs. Cronos Group (NASDAQ:CRON) Financial Comparison

Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and Cronos Group (NASDAQ: CRON - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation. Institutional and Insider Ownership 36.8% of Aurinia Pharmaceuticals

Apr 26, 2026 09:12 PM • defenseworld.net
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of “Hold” by Analysts

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of “Hold” by Analysts

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH - Get Free Report) (TSE: AUP) has earned an average recommendation of "Hold" from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target

Apr 05, 2026 10:21 PM • defenseworld.net
Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance

Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance

Aurinia Pharmaceuticals has undergone a major management overhaul, with fund manager and activist investor Kevin Tang appointed as the CEO. AUPH's COO and CFO have also been replaced. Lupkynis's net product sales reached $271.3M in 2025, up 25.5% YoY, with 2026 guidance for $305M–$315M, possibly conservative given the company's previous beat of initial 2025 guidance. Aritinercept will be evaluated in two autoimmune diseases, with one clinical study already underway and another set to commence in H1 2026, although the exact indications have not been disclosed.

Mar 27, 2026 12:15 PM • seekingalpha.com
MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition

MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the following statement in response to the Company's announcement that Kevin Tang has been appointed Chief Executive Officer, effective immediately. Antoine Khalife, Founder of MKT Capital, stated: “Today marks a watershed moment for Aurinia shareholders. Since 2019,.

Mar 23, 2026 07:00 AM • businesswire.com
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress. Financial Results Total Revenue: For the three and twelve months ended December 31, 2025, total revenue was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million, respectively, for the same periods of 2024.

Feb 26, 2026 01:00 AM • businesswire.com
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26, 2026. Aurinia's management team will host a webcast and conference call on February 26, 2026, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-8029 / +1 201-689-8029.

Feb 19, 2026 01:00 AM • businesswire.com
Aurinia Pharmaceuticals (NASDAQ:AUPH) and Merck KGaA (OTCMKTS:MKKGY) Head-To-Head Analysis

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Merck KGaA (OTCMKTS:MKKGY) Head-To-Head Analysis

Merck KGaA (OTCMKTS:MKKGY - Get Free Report) and Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Institutional and Insider Ownership 0.1% of Merck KGaA

Jan 31, 2026 08:24 PM • defenseworld.net

Price Targets